Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect (D-MNA) to treat basal cell …
Medicus Pharma Submits Orphan Drug Application for SkinJect Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present Phase 1 clinical data for its investigational drug Teverelix at the American Association of Clinical Endocrinology Annual Meeting, …
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone antagonist, at the American Association of …
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed …
Medicus Submits Phase 2 Study Design for Teverelix to FDA Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) issued a clarification of previously reported Phase 2 trial results for its SkinJect therapy in nodular basal cell carcinoma, the company said.
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it has submitted an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration for teverelix, an investigational …
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will host a business update webcast on Thursday, March 26, at 11:30 a.m. Eastern time, featuring Dr. Babar K. Rao, …
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) reported additional data from its Phase 2 SKNJCT-003 clinical study evaluating the SkinJect microneedle delivery system for the treatment of basal cell …
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array treatment for basal cell carcinoma of the skin.
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will participate in the 38th Annual Roth Conference, scheduled for March 22 to March 24 in Dana Point, California.
Medicus Pharma to Present Drug Development Programs at Roth Conference Read More